The Food and Drug Administration (FDA) has proposed changes to drug establishment registration and drug listing regulations to address emerging manufacturing models and strengthen oversight of foreign producers.
The proposal would create a pathway for distributed manufacturing establishments (DMEs) to register as a single entity, even if they operate multiple